

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231 on

Atty Docket No. SUN-64P  
Client Ref.: S97-118

December 21, 1998  
142198 Andrew J. Feld  
Date Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Koichi Akashi, et al.

Serial No.: 08/918,537

Filing Date: August 22, 1997

Title: *Mammalian Common Lymphoid Progenitor Cell*



Group Art Unit: Unassigned

Examiner: Unassigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**Under 37 C.F.R. § 1.97**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration.

     The information listed below is being submitted to the Office promptly after it has become known to applicant(s) and is being submitted prior to the final determination on patentability by the Office.

  X   The information listed below was cited in an International (PCT) Search Report dated December 16, 1998, in a PCT application corresponding to the above-identified U.S. application. A copy of the Search Report, including an indication of the purported relevance of the cited documents, is enclosed

herewith. Copies of the information are submitted herewith. The Examiner is requested to make this information of official record in the application.

— The references identified below were disclosed in parent application Serial No. and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d).

Applicants have enclosed the completed PTO-1449 form(s) and would appreciate the Examiner's initialing and returning the form(s) to indicate that the references have been reviewed and made of record. The references are as follows:

U.S. Patent Documents:

**None Enclosed**

Foreign Patent Documents:

**None Enclosed**

Other Documents:

**Galy, Anne, et al.**, "Human T,B, Natural Killer, and Dendritic Cells Arise From A Common Bone Marrow Progenitor Cell Subset," *Immunity* (Oct. 1995) Vol. 3:459-473.

**Kawamoto, Hiroshi, et al.**, "Direct Evidence For The Commitment Of Hematopoietic Stem Cells To T,B and Myeloid Lineages In Murine Fetal Liver," *International Immunology* (1997) Vol. 9, No. (7):1011-1019.

**Koguma, Masahito, et al.**, "Selective Proliferation Of Lymphoid Cells From Lineage<sup>-</sup> c-Kit<sup>+</sup> Sca-1<sup>+</sup> Cells By A Clonal Bone Marrow Stromal Cell Line," *Experimental Hematology* (1998) Vol. 26:280-287.

**Kondo, Motonari, et al.**, "Identification Of Clonogenic Common Lymphoid Progenitors In Mouse Bone Marrow," *Cell* (Nov. 28, 1997) Vol. 91:661-672.

**Matsuzaki, Yumi, et al.**, "Characterization Of c-Kit Positive Intrathymic Stem Cells That Are Restricted To Lymphoid Differentiation," *J. Exp. Med.* (Oct. 1993) Vol. 178:1283-1292.

**Moore, Thomas A.**, "T-Cell Lineage Commitment And Cytokine Responses Of Thymic Progenitors," *Blood* (Sept. 1, 1995) Vol. 86, No. (5):1850-1860.

**Orlic, Donald, et al.**, "Interleukin-7R $\alpha$  mRNA Expression Increases As Stem Cells Differentiate Into T and B Lymphocyte Progenitors," *Experimental Hematology* (1997) Vol. 25:217-222.

**Palacios, Ronald, et al.**, "Developmentally Regulated Cell Surface Expression And Function Of c-Kit Receptor During Lymphocyte Ontogeny In The Embryo And Adult Mice," *Development* (August 1992) Vol. 115, No. (4):1133-1147.

**Veiby, Ole P., et al.**, "Combined Signaling Through Interleukin-7 Receptors And flt3 But Not c-Kit Potently And Selectively Promotes B-Cell Commitment And Differentiation From Uncommitted Murine Bone Marrow Progenitor Cells," *Blood* (August 15, 1996) Vol. 88, No. (4):1256-1265.

**Veiby, Ole P., et al.**, "Bidirectional Effect Of Interleukin-10 On Early Murine B-Cell Development: Stimulation Of flt3-Ligand Plus Interleukin-7-Dependent Generation Of CD19<sup>-</sup> ProB Cells From Uncommitted Bone Marrow Progenitor Cells And Growth Inhibition Of CD19<sup>+</sup> ProB Cells," *Blood* (Dec. 1, 1997) Vol. 90, No. (11):4321-4331.

This Supplemental Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


  X   As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Supplemental Information Disclosure Statement. If, for any reason, a fee is found to be required, our Deposit Account No. 18-0580 may be charged therefor.

       The appropriate certification under 37 C.F.R. §1.97(e) accompanies this paper.

\_\_\_\_\_ The \$230.00 fee required by 37 C.F.R. §1.97(c) and set forth in 37 C.F.R. 1.17(p) accompanies this disclosure statement. The Office is hereby authorized to charge any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to our Deposit Account No. 18-0580.

Respectfully submitted,

By:

  
Pamela Sherwood  
Registration No. 36,677

BOZICEVIC & REED LLP  
285 Hamilton Avenue, Suite 200  
Palo Alto, CA 94301  
Telephone: (650) 327-3400  
Fax: (650) 327-3231

F:\DOCUMENT\Stanford (SUN)\SUN-64P\Supplemental Information Disclosure Statement.wpd